NASDAQ:AUPH Aurinia Pharmaceuticals Q1 2026 Earnings Report $16.97 +0.18 (+1.07%) Closing price 06/30/2026 04:00 PM EasternExtended Trading$17.01 +0.04 (+0.24%) As of 06/30/2026 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Aurinia Pharmaceuticals EPS ResultsActual EPS$0.25Consensus EPS $0.18Beat/MissBeat by +$0.07One Year Ago EPSN/AAurinia Pharmaceuticals Revenue ResultsActual Revenue$77.71 millionExpected Revenue$76.98 millionBeat/MissBeat by +$731.00 thousandYoY Revenue GrowthN/AAurinia Pharmaceuticals Announcement DetailsQuarterQ1 2026Date5/7/2026TimeBefore Market OpensConference Call DateThursday, May 7, 2026Conference Call Time8:00AM ETUpcoming EarningsAurinia Pharmaceuticals' Q2 2026 earnings is estimated for Thursday, July 30, 2026, based on past reporting schedules, with a conference call scheduled at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Aurinia Pharmaceuticals Earnings HeadlinesIs Aurinia Pharmaceuticals Inc. (AUPH) A Good Stock To Buy Now?June 29 at 8:22 PM | finance.yahoo.comAurinia Pharmaceuticals Inc (NASDAQ:AUPH) Given Average Rating of "Hold" by AnalystsJune 20, 2026 | americanbankingnews.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now. | Stansberry Research (Ad)Aurinia Pharmaceuticals and four more stocks see activist actionJune 12, 2026 | msn.comA Fresh Look At Aurinia Pharmaceuticals (AUPH) Valuation After Recent Share Price ConsolidationJune 11, 2026 | finance.yahoo.comAurinia Pharmaceuticals' (AUPH) CEO Bought 815,000 Shares for $12.5 MillionJune 7, 2026 | fool.comSee More Aurinia Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aurinia Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aurinia Pharmaceuticals and other key companies, straight to your email. Email Address About Aurinia PharmaceuticalsAurinia Pharmaceuticals (NASDAQ:AUPH). is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline. The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S. Food and Drug Administration for the treatment of adult patients with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus. Beyond lupus nephritis, Aurinia is investigating voclosporin in additional indications such as focal segmental glomerulosclerosis (FSGS) and dry eye disease, with several ongoing clinical trials to evaluate safety and efficacy. Founded in the early 1990s, Aurinia is headquartered in Victoria, British Columbia, and maintains a presence in North America to support its clinical and commercial activities. The company’s leadership team comprises experienced professionals in drug development, regulatory affairs and commercial operations, guiding Aurinia through pivotal clinical milestones and into its initial product launch. As Aurinia continues to expand its pipeline and explore partnerships, it remains committed to addressing unmet needs in autoimmune disease management.View Aurinia Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Wall Street Still Sees Massive Upside for AeroVironment StockManchester United’s Stock Rally Faces a Test Beyond Old TraffordBest Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs ProofPalantir’s Rough 2026 Start Raises a Bigger Question About Its AI MoatWinnebago Misses Estimates, But Surges 14% After EarningsBlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings AloneTrip.com’s Selloff Raises a Bigger Question About Its Travel Recovery Story Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
